| Literature DB >> 27821943 |
Ahmad H Alghadir1, Sami A Gabr2, Einas S Al-Eisa1.
Abstract
This study aimed to evaluate the effects of green tea and supervised exercise training interventions on improvement of disease activity and bone metabolism markers in rheumatoid arthritis patients.Entities:
Keywords: Aerobic exercise; Green tea; Rheumatoid arthritis
Year: 2016 PMID: 27821943 PMCID: PMC5088134 DOI: 10.1589/jpts.28.2820
Source DB: PubMed Journal: J Phys Ther Sci ISSN: 0915-5287
Demographics and baseline characteristics of the patients with rheumatoid arthritis (RA) enrolled in this study
| Parameters | I | GT | EX | I + GT | I + EX | GT + EX |
|---|---|---|---|---|---|---|
| No. of patients | 20 | 20 | 20 | 20 | 20 | 20 |
| Gender (M/F) | (16/4) | (15/5) | (17/3) | (12/8) | (13/7) | (14/6) |
| Mean Age (yrs) | 55.6 ± 12.41 | 57.3 ± 11.2 | 52.6 ± 9.4 | 48.9 ± 7.1 | 45.9 ± 6.3 | 51.6 ± 3.8 |
| BMI (kg/m2) | 24.6 ± 2.18 | 23.9 ± 3.2 | 24.3 ± 1.2 | 24.6 ± 3.15 | 25.2 ± 3.2 | 22.9 ± 4.13 |
| Duration of RA (yrs) | 12.9 ± 3.01 | 11.9 ± 2.03 | 13.1 ± 1.03 | 12.5 ± 4.05 | 10.8 ± 3.02 | 12.3 ± 2.01 |
| DAS28-ESR | 6.6 ± 0.65 | 5.4 ± 0.43 | 6.7 ± 0.23 | 5.7 ± 0.31 | 5.1 ± 0.40 | 6.2 ± 0.37 |
| mHAQ score | 4.5 ± 1.38 | 5.1.3 ± 3.5 | 7.1 ± 3.21 | 6.9 ± 1.27 | 8.1 ± 2.1 | 9.5 ± 1.4 |
DAS28: Disease Activity Score-28; mHAQ: modified Stanford Health Assessment Questionnaire score; BMI: body mass index; I: infliximab group; GT: green tea group; EX: exercise group; I + GT: infliximab + green tea; I + EX:infliximab + exercise group; GT + EX: green tea + exercise group
Phenolic compounds content (mg/g) and free-radical scavenging activities of 350 mL aqueous green tea extract (AGTE) using liquid chromatography and spectrophotometry analysis
| Parameters | Phenolic contents (mg/g) |
|---|---|
| Phenolic components: | |
| Catechins (EGCG, ECG) | 589 |
| Caffeine | 96 |
| Chlorogenic acid | 25.34 |
| Pyrogallol | 18.5 |
| Vanillic acid | 6.8 |
| Synergic acid | 4.5 |
| Salycillic acid | 3.58 |
| POH Benzoic acid | 0.91 |
| Ferulic acid | 0.74 |
| P-Coumaric acid | 0.16 |
| Coumarin | 0.18 |
| Naringenin | 2.1 |
| AGTE scavenging activities: | Free-radical scavenging activities at 64 µg/ml |
| Percentage of inhibition of DPPH reagent | 96.50% |
| Percentage of inhibition of NBT/ Riboflavin reagent | 89.60% |
Biomarkers and disease activity levels of RA patients receiving infliximab, green tea therapy, and/or exercise training
| Parameters | Treatment groups | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I (n=20) | GT (n=20) | EX (n=20) | I+GT (n=20) | I+EX (n=20) | GT+EX (n=20) | |||||||
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| CRP | 5.29 ± 0.7 | 2.84 ± 0.8b | 6.2 ± 0.52 | 2.5 ± 0.7b | 7.1 ± 0.45 | 4.9 ± 0.7b | 6.9 ± 0.5 | 1.9 ± 0.4b | 9.2 ± 0.7 | 3.9 ± 0.5b | 6.2 ± 0.5 | 1.8 ± 0.4b |
| ESR | 68.7 ± 9.09 | 45.9 ± 8.7b | 65.7 ± 11.1 | 42.4 ± 6.8b | 71.5 ± 13.1 | 56.4 ± 9.3b | 78.5 ± 10.1 | 36.4 ± 6.3b | 65.5 ± 11.3 | 51.4 ± 7.4b | 60.7 ± 11.1 | 32.2 ± 3.6b |
| DAS28 | 6.6 ± 0.7 | 4.9 ± 0.4b | 5.4 ± 0.3 | 2.1 ± 0.3b | 6.7 ± 0.2 | 5.3 ± 0.5b | 5.7 ± 0.3 | 3.5 ± 0.42b | 5.1 ± 0.40 | 4.5 ± 0.6b | 6.2 ± 0.4 | 2.5 ± 0.41b |
| SJC | 14.3 ± 2.8 | 9.6 ± 1.62b | 13.2 ± 2.5 | 8.5 ± 1.3b | 12.7 ± 2.9 | 10.5 ± 1.3b | 11.2 ± 1.5 | 7.5 ± 1.2b | 11.8 ± 2.3 | 9.7 ± 1.7b | 11.2 ± 1.5 | 6.5 ± 1.21b |
| TJC | 7.12 ± 1.8 | 4.35 ± 0.9a | 6.7 ± 1.9 | 4.2 ± 0.8b | 8.5 ± 3.6 | 5.8 ± 0.5b | 8.3 ± 3.9 | 3.9 ± 0.6b | 8.65 ± 3.6 | 4.6 ± 0.5b | 7.9 ± 2.9 | 3.6 ± 0.6b |
| mHAQ | 4.8 ± 1.4 | 2.9 ± 0.9b | 5.1 ± 3.5 | 1.9 ± 1.4b | 5.4 ± 3.2 | 3.2 ± 1.3b | 6.9 ± 1.5 | 3.2 ± 1.2b | 7.2 ± 2.1 | 5.4 ± 2.6b | 7.3 ± 1.4 | 2.7 ± 2.3b |
| NTX | 87.1 ± 16.0 | 56.5 ± 5.1b | 82.1 ± 11.0 | 47.5 ± 3.6b | 89.5 ± 18.0 | 68 ± 6.2b | 79.3 ± 12.0 | 37.4 ± 8.2b | 69.5 ± 12.3 | 51.9 ± 4.2b | 85.4 ± 11.9 | 36.8 ± 5.8b |
| DPD | 11.22 ± 0.9 | 8.38 ± 0.7b | 10.6 ± 0.6 | 7.4 ± 0.4b | 12.8 ± 0.5 | 9.4 ± 0.3b | 10.5 ± 0.9 | 6.6 ± 0.3b | 13.2 ± 0.4 | 7.6 ± 0.3b | 11.8 ± 0.7 | 4.5 ± 0.5b |
| sBAP | 15.66 ± 6.2 | 16.5 ± 5.5a | 18.7.6 ± 7.5 | 24.6 ± 4.5a | 16.1 ± 6.3 | 18.1 ± 3.0a | 15.7 ± 5.9 | 26.5 ± 7.0a | 12.8 ± 5.7 | 19.6 ± 4.2a | 18.3 ± 3.7 | 35.3 ± 4.5a |
Data are shown as mean ± SD values. ap<0.05 vs. pre (before treatment or baseline)., bp<0.01 vs. pre (before treatment or baseline). DAS28: Disease Activity Score-28; mHAQ: modified Stanford Health Assessment Questionnaire score; BMI: body mass index; I: infliximab group; GT: green tea group; EX: exercise group; I + GT: infliximab + green tea; I + EX, infliximab + exercise group; GT + EX, green tea + exercise group. SJC: swollen joints counts; TJC: tender joints count. DPD (nM/MCl): deoxypyridinoline; NTX (nM BCE/mM Cr): cross-linked N-telopeptides of type I collagen; sBAP(U/l): serum bone alkaline phosphatase. CRP (mg/dl): C-reactive protein; ESR (mm): erythrocyte sedimentation rate
Correlation between the bone resorption markers and the changes in disease activity of RA patients treated with infliximab, green tea, or a supervised aerobic training program
| Parameters | I group (n=20) | GT group (n=20) | EX group (n=20) | I + GT (n=20) | I + EX (n=20) | GT +EX (n=20) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTX | DPD | NTX | DPD | NTX | DPD | NTX | DPD | NTX | DPD | NTX | DPD | |
| R | R | R | R | R | R | R | R | R | R | R | R | |
| CRP | 0.045a | 0.067 b | 0.123a | 0.078b | 0.118a | 0.008b | 0.138a | 0.029b | 0.149a | 0.039b | 0.228a | 0.078b |
| ESR | 0.050a | 0.221b | 0.231a | 0.125b | 0.125a | 0.005b | 0.175a | 0.015b | 0.195a | 0.045b | 0.345a | 0.085b |
| SJC | 0.635a | 0.165b | 0.550a | 0.240b | 0.130a | 0.125b | 0.230a | 0.185b | 0.180a | 0.295b | 0.180a | 0.035b |
| TJC | 0.124a | 0.004b | 0.347a | 0.255b | 0.147a | 0.058b | 0.167a | 0.098b | 0.189a | 0.168b | 0.187a | 0.098b |
| mHAQ score | 0.475a | 0.457b | 0.175a | 0.132b | 0.158a | 0.039b | 0.179a | 0.082b | 0.289a | 0.172b | 0.218a | 0.085b |
| DAS28-ESR | 0.125a | 0.114b | 0.345a | 0.142b | 0.525a | 0.048b | 0.435a | 0.059b | 0.345a | 0.159b | 0.415a | 0.095b |
a Correlation is significant at (p<0.01). b Correlation is significant at (p<0.001). I: infliximab group; GT: green tea group; EX: exercise group; I + GT: infliximab + green tea; I + EX: infliximab + exercise group; GT + EX: green tea + exercise group. SJC: swollen joints counts; TJC: tender joints counts. DPD (nM/MCl): deoxypyridinoline; NTX (nM BCE/mM Cr): cross-linked N-telopeptides of type I collagen; CRP (mg/dl): C-reactive protein; ESR (mm): erythrocyte sedimentation rate
Summary of therapeutic responses criteria at week 24
| Clinical end point | Treatment groups | |||||
|---|---|---|---|---|---|---|
| I (n=20) | GT (n=20) | EX (n=20) | I+GT (n=20) | I+EX (n=20) | GT+EX (n=20) | |
| ACR20 n (%) | 10 (50%) | 5 (25%) | 8 (40%) | 2 (10%) | 10 (50%) | 2 (10%) |
| ACR50 n (%) | 7 (35%) | 6 (30%) | 9 (45%) | 7 (35%) | 2 (10%) | 6 (30%) |
| ACR70 n (%) | 3 (15%) | 9 (45%) | 3 (15%) | 11 (55%) | 8 (40%) | 12 (60%) |
| EULAR response score | ||||||
| Good (>1.2%): | 9 (45%) | 10 (50%) | 9 (45%) | 11 (55%) | 12 (60%) | 15 (75%) |
| Moderate (0.6 to −1.2%) | 5 (25%) | 9 (45%) | 5 (25%) | 8 (44%) | 3 (15%) | 4 (20%) |
| No response (>0.6%) | 6 (30%) | 1 (5%) | 6 (30%) | 1 (5%) | 5 (25%) | 1 (5%) |
ACR20: American College of Rheumatology 20% improvement; ACR50: American College of Rheumatology 50% improvement; ACR70: American College of Rheumatology 70% improvement. I: infliximab group; GT: green tea group; EX: exercise group; I + GT: infliximab + green tea; I + EX: infliximab + exercise group; GT + EX: green tea + exercise group; EULAR: European League Against Rheumatism